SMAD3 and non-small cell lung carcinoma: Moreover, in non-small cell lung carcinoma (NSCLC), the activation of Smad3 in N2 TANs was negatively correlated with the N1 population and patient survival, suggesting heterogeneity in neutrophil tumor subset infiltration may impact tumor progression/regression [13].